🏢 官网IRVNDADoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 10-21(美东日)仅日期·时区推断·⟳ 抓取 05:43:29回填·⚡ 决策 10-22 05:44:42·5.8 天前
Vanda Pharmaceuticals宣布将于2026年10月28日盘后发布Q3财报并召开电话会（纯日程预告）
本稿为例行财报日期与电话会安排通知，不含收入、利润、EPS、指引、订单或临床/监管等任何增量事实，且同一具体催化（同份PR Newswire稿件）已在72小时窗口内处理并判不做，无新增信息。
📄 原文VNDA↗ 原文
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
October 21, 2026 Conference Call and Webcast to Follow WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals…
不做 Vanda Pharmaceuticals Inc.（VNDA.US）
纯财报发布日期/电话会程序性预告（save-the-date），未披露任何收入、利润、EPS、指引、订单或临床/监管增量，方向中性、无预期差与交易edge；且同一PR Newswire稿件已在72小时窗口处理过，无新增信息。真正催化在2026-10-28盘后实际Q3财报，届时再独立研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Vanda仅预告Q3财报将于10月28日盘后发布及电话会安排，无任何财务或经营增量，属程序性日历事件，无方向与交易edge；真正催化在10月28日实际财报，届时再研判。
主要风险
- 真正的方向性催化在2026-10-28盘后实际Q3财报，当前稿件不提供任何可交易信息。
先例如何影响了这次决策
对本次决策的影响:确认以NO_INCREMENTAL_FACT回避，不设tp/sl，等待10-28实际财报。
方向:无方向性增量，不适用先例定价；多家药企/公司同类财报日期预告（Supernus、Amarin、Phathom等）本臂均判不做。
涨幅量级:纯save-the-date公告无业绩增量，无需校准涨跌幅。
形态:财报日期通知不构成催化，真正波动发生在实际财报披露当日。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 2,187 ms
{"result": "search_processed_events:agent query=`vanda pharmaceuticals q3 2026 earnings date october 28 conference call | vanda vnda third quarter 2026 financial results announcement`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、27390 条本臂决策(完整)，返回 11 条候选。\n• 10-21 21:44 UTC(北京 10-22 05:44) [bm25:67%,ticker]
原文全文
展开原文 · 2,110 字
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
October 21, 2026
Conference Call and Webcast to Follow
WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the
third quarter 2026 on Wednesday, October 28, 2026, after the market closes.
Vanda will host a conference call at 4:30 PM ET on Wednesday, October 28, 2026, during which management will discuss the third quarter 2026
financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963
(international) and use passcode 1178705.
The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at
least 15 minutes early to register, download, and install any necessary audio software.
A replay of the call will be available on Wednesday, October 28, 2026, beginning at 8:30 PM ET and will be accessible until Wednesday, November 4,
2026, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode
number is 1178705.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high
unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us
on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-third-quarter-
2026-financial-results-on-october-28-2026-302916061.html
SOURCE Vanda Pharmaceuticals Inc.
October 21, 2026
Conference Call and Webcast to Follow
WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the
third quarter 2026 on Wednesday, October 28, 2026, after the market closes.
Vanda will host a conference call at 4:30 PM ET on Wednesday, October 28, 2026, during which management will discuss the third quarter 2026
financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963
(international) and use passcode 1178705.
The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at
least 15 minutes early to register, download, and install any necessary audio software.
A replay of the call will be available on Wednesday, October 28, 2026, beginning at 8:30 PM ET and will be accessible until Wednesday, November 4,
2026, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode
number is 1178705.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high
unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us
on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-third-quarter-
2026-financial-results-on-october-28-2026-302916061.html
SOURCE Vanda Pharmaceuticals Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
6e4dfd0d00· 2026-10-22 05:44 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前